Lilly’s Curevo deal turns AAHI’s adjuvant science into a late-stage vaccine opportunity
Find out how AAHI’s SLA-SE adjuvant could shape Lilly’s next-generation shingles vaccine strategy after the Curevo acquisition.
Why Sanofi’s $2.2bn Dynavax deal is a high-stakes bet on adult vaccines
Sanofi to acquire Dynavax for $2.2B to boost adult vaccines. Find out how HEPLISAV-B and Z-1018 fit into Sanofi’s global immunization strategy.